Alzheimer's disease & dementia

Phase III aducanumab trials for Alzheimer's disease stopped early

Pharmaceutical companies Biogen and Eisai today (Thursday 21 March) announced they are to discontinue two phase III trials of the Alzheimer's drug aducanumab. The ENGAGE and EMERGE trials were designed to evaluate the efficacy ...

Medications

The pharmaceutical ethics of stunning drug-price increases

Last week Turing Pharmaceuticals, a startup run by a former hedge-fund manager, raised the price of Daraprim—the standard treatment for toxoplasmosis—from $13.50 to $750 a tablet soon after acquiring the drug from another ...

page 15 from 40